Altered immunoregulatory profile during anti-tumour necrosis factor treatment of patients with inflammatory bowel disease

Clinical and Experimental Immunology

Volumn 169, Issue 2, 2012, Pages 137-147

  Grundstrom J ^a   Linton, L ^a   Thunberg, S ^a   Forsslund, H ^a   Janczewska, I ^b   Befrits, R ^c   van Hage, M ^a   Gafvelin, G ^a   Eberhardson, M ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Crohn's disease; Inflammatory bowel disease; Regulatory T cell; TNF RII; Ulcerative colitis

Indexed keywords

ADALIMUMAB; BUDESONIDE; CD69 ANTIGEN; INFLIXIMAB; INTERLEUKIN 10; PREDNISOLONE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RECEPTOR 2;

ARTICLE; CD25+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; CROHN DISEASE; DRUG MECHANISM; EFFECTOR CELL; ENTERITIS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOREGULATION; INTESTINE BIOPSY; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TREATMENT DURATION; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTORS;

EID: 84863581114     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2012.04600.x     Document Type: Article

References (47)

1. Cho JH. Inflammatory bowel disease: genetic and epidemiologic considerations. World J Gastroenterol 2008; 14:338-47.
2. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004; 126:1504-17.
3. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003; 3:521-33.
4. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3:390-407.
5. Loftus EV Jr, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut 2000; 46:336-43.
6. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007; 369:1627-40.
7. Doering J, Begue B, Lentze MJ etal. Induction of T lymphocyte apoptosis by sulphasalazine in patients with Crohn's disease. Gut 2004; 53:1632-8.
8. MacDonald TT, Monteleone G, Pender SL. Recent developments in the immunology of inflammatory bowel disease. Scand J Immunol 2000; 51:2-9.
9. Eastaff-Leung N, Mabarrack N, Barbour A, Cummins A, Barry S. Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. J Clin Immunol 2010; 30:80-9.
10. Holmen N, Lundgren A, Lundin S etal. Functional CD4+CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity. Inflamm Bowel Dis 2006; 12:447-56.
11. Makita S, Kanai T, Oshima S etal. CD4+CD25bright T cells in human intestinal lamina propria as regulatory cells. J Immunol 2004; 173:3119-30.
12. Parronchi P, Romagnani P, Annunziato F etal. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol 1997; 150:823-32.
13. Fuss IJ, Neurath M, Boirivant M etal. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996; 157:1261-70.
14. Duerr RH, Taylor KD, Brant SR etal. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314:1461-3.
15. Hanauer SB, Feagan BG, Lichtenstein GR etal. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359:1541-9.
16. Rutgeerts P, Sandborn WJ, Feagan BG etal. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353:2462-76.
17. Li Z, Arijs I, De Hertogh G etal. Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab. Inflamm Bowel Dis 2010; 16:1299-310.
18. Hvas CL, Kelsen J, Agnholt J, Dige A, Christensen LA, Dahlerup JF. Discrete changes in circulating regulatory T cells during infliximab treatment of Crohn's disease. Autoimmunity 2010; 43:325-33.
19. Ricciardelli I, Lindley KJ, Londei M, Quaratino S. Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease. Immunology 2008; 125:178-83.
20. Boschetti G, Nancey S, Sardi F, Roblin X, Flourie B, Kaiserlian D. Therapy with anti-TNFalpha antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases. Inflamm Bowel Dis 2011; 17:160-70.
21. Saruta M, Yu QT, Fleshner PR etal. Characterization of FOXP3+CD4+ regulatory T cells in Crohn's disease. Clin Immunol 2007; 125:281-90.
22. Thunberg S, Gafvelin G, Nord M etal. Allergen provocation increases TH2-cytokines and FOXP3 expression in the asthmatic lung. Allergy 2010; 65:311-8.
23. Gronlund H, Bergman T, Sandstrom K etal. Formation of disulfide bonds and homodimers of the major cat allergen Fel d 1 equivalent to the natural allergen by expression in Escherichia coli. J Biol Chem 2003; 278:40144-51.
24. Burgler S, Ouaked N, Bassin C etal. Differentiation and functional analysis of human T(H)17 cells. J Allergy Clin Immunol 2009; 123:588-95. 95 e1-7.
25. Wilson NJ, Boniface K, Chan JR etal. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8:950-7.
26. Acosta-Rodriguez EV, Rivino L, Geginat J etal. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007; 8:639-46.
27. Mjosberg J, Berg G, Jenmalm MC, Ernerudh J. FOXP3+ regulatory T cells and T helper 1, T helper 2, and T helper 17 cells in human early pregnancy decidua. Biol Reprod 2010; 82:698-705.
28. Chen X, Subleski JJ, Hamano R, Howard OM, Wiltrout RH, Oppenheim JJ. Co-expression of TNFR2 and CD25 identifies more of the functional CD4+FOXP3+ regulatory T cells in human peripheral blood. Eur J Immunol 2010; 40:1099-106.
29. Daniel C, Sartory N, Zahn N, Geisslinger G, Radeke HH, Stein JM. FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells. J Immunol 2007; 178:2458-68.
30. Ogino H, Nakamura K, Ihara E, Akiho H, Takayanagi R. CD4(+)CD25(+) regulatory T cells suppress Th17-responses in an experimental colitis model. Dig Dis Sci 2011; 56:376-86.
31. Watanabe K, Rao VP, Poutahidis T etal. Cytotoxic-T-lymphocyte-associated antigen 4 blockade abrogates protection by regulatory T cells in a mouse model of microbially induced innate immune-driven colitis. Infect Immun 2008; 76:5834-42.
32. Fantini MC, Becker C, Tubbe I etal. Transforming growth factor beta induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis. Gut 2006; 55:671-80.
33. Shen C, de Hertogh G, Bullens DM etal. Remission-inducing effect of anti-TNF monoclonal antibody in TNBS colitis: mechanisms beyond neutralization? Inflamm Bowel Dis 2007; 13:308-16.
34. Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL. Inhibition of Th1 responses prevents inflammatory bowel disease in SCID mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994; 1:553-62.
35. Ehrenstein MR, Evans JG, Singh A etal. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004; 200:277-85.
36. Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006; 108:253-61.
37. Nagar M, Jacob-Hirsch J, Vernitsky H etal. TNF activates a NF-kappaB-regulated cellular program in human CD45RA-regulatory T cells that modulates their suppressive function. J Immunol 2010; 184:3570-81.
38. Housley WJ, Adams CO, Nichols FC etal. Natural but not inducible regulatory T cells require TNF-{alpha} signaling for in vivo function. J Immunol 2011; 186:6779-87.
39. Atreya R, Zimmer M, Bartsch B etal. Anti-TNF antibodies target T-cell apoptosis in inflammatory bowel diseases via TNFR2 and intestinal CD14+ macrophages. Gastroenterology 2011; 141:2026-38.
40. Ling EM, Smith T, Nguyen XD etal. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004; 363:608-15.
41. Akdis M, Verhagen J, Taylor A etal. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004; 199:1567-75.
42. Grindebacke H, Wing K, Andersson AC, Suri-Payer E, Rak S, Rudin A. Defective suppression of Th2 cytokines by CD4CD25 regulatory T cells in birch allergics during birch pollen season. Clin Exp Allergy 2004; 34:1364-72.
43. Yuan YH, ten Hove T, The FO, Slors JF, van Deventer SJ, te Velde AA. Chemokine receptor CXCR3 expression in inflammatory bowel disease. Inflamm Bowel Dis 2001; 7:281-6.
44. Aeberli D, Seitz M, Juni P, Villiger PM. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors. Rheumatology (Oxf) 2005; 44:172-5.
45. Chabaud M, Durand JM, Buchs N etal. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999; 42:963-70.
46. Zaba LC, Cardinale I, Gilleaudeau P etal. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007; 204:3183-94.
47. Kobayashi T, Okamoto S, Hisamatsu T etal. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut 2008; 57:1682-9.